Skip to main content
. 2019 Dec 19;20(Suppl 1):81. doi: 10.1186/s40360-019-0358-y

Fig. 1.

Fig. 1

Plasma concentration versus time of TAM and NDTAM (upper panels) and 4-HTAM and END (lower panels) observed during a dosing interval of TAM therapy (20 mg/day) in all investigated TAM-treated breast cancer patients (n = 40). The value of 6 ng/ml END corresponds to the threshold associated with efficacy